Payment overview · 2025
General Payments
$16.47
1 reported records · 1 companies
Healthcare provider profile · identity verified
Amjad Iqbal, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · POUGHKEEPSIE, NY · NPI 1629296223
Verified facts
What the public records show
CMS Open Payments records show Amjad Iqbal, M.D. received $16.47 in general payments during 2025 across 1 reported records.
Novartis Pharmaceuticals Corporation accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.47 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $16.47 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
195 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 900 | 63 |
| Atorvastatin Calcium | Atorvastatin Calcium | 652 | 101 |
| Gabapentin | Gabapentin | 469 | 65 |
| Furosemide | Furosemide | 463 | 69 |
| Potassium Chloride | Potassium Chloride | 419 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 385 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 354 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 341 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 310 | 43 |
| Donepezil Hcl | Donepezil Hcl | 263 | 30 |
| Xarelto | Rivaroxaban | 224 | 17 |
| Losartan Potassium | Losartan Potassium | 217 | 32 |
| Lisinopril | Lisinopril | 211 | 35 |
| Sertraline Hcl | Sertraline Hcl | 210 | 25 |
| Carvedilol | Carvedilol | 203 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 33 |
| Entresto | Sacubitril/Valsartan | 195 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 191 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 190 | 21 |
| Metformin Hcl | Metformin Hcl | 184 | 23 |
| Warfarin Sodium | Warfarin Sodium | 182 | suppressed |
| Mirtazapine | Mirtazapine | 158 | 26 |
| Farxiga | Dapagliflozin Propanediol | 145 | 11 |
| Januvia | Sitagliptin Phosphate | 141 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 140 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 21 |
| Levetiracetam | Levetiracetam | 128 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 122 | 15 |
| Latanoprost | Latanoprost | 120 | 17 |
| Memantine Hcl | Memantine Hcl | 119 | 16 |
| Baclofen | Baclofen | 118 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 17 |
| Omeprazole | Omeprazole | 116 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 13 |
| Prednisone | Prednisone | 108 | 23 |
| Trazodone Hcl | Trazodone Hcl | 99 | 18 |
| Spironolactone | Spironolactone | 96 | 16 |
| Simvastatin | Simvastatin | 87 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 16 |
| Methenamine Hippurate | Methenamine Hippurate | 84 | suppressed |
| Allopurinol | Allopurinol | 83 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 83 | 11 |
| Tramadol Hcl | Tramadol Hcl | 82 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 75 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 73 | 13 |
| Risperidone | Risperidone | 73 | suppressed |
| Sucralfate | Sucralfate | 73 | suppressed |
| Finasteride | Finasteride | 71 | 12 |
| Olanzapine | Olanzapine | 71 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 37 |
| Rivastigmine | Rivastigmine Tartrate | 68 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 25 |
| Atenolol | Atenolol | 67 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 67 | suppressed |
| Torsemide | Torsemide | 65 | 12 |
| Myrbetriq | Mirabegron | 63 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 61 | suppressed |
| Lamotrigine | Lamotrigine | 61 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 60 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 58 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 57 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 54 | 53 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 54 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 52 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 52 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 12 |
| Aripiprazole | Aripiprazole | 51 | suppressed |
| Jardiance | Empagliflozin | 51 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 51 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 50 | suppressed |
| Linzess | Linaclotide | 49 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 49 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 49 | suppressed |
| Trulicity | Dulaglutide | 49 | suppressed |
| Amantadine | Amantadine Hcl | 48 | suppressed |
| Famotidine | Famotidine | 48 | suppressed |
| Lorazepam | Lorazepam | 48 | 13 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 47 | suppressed |
| Gemtesa | Vibegron | 47 | suppressed |
| Tradjenta | Linagliptin | 47 | suppressed |
| Alprazolam | Alprazolam | 46 | suppressed |
| Lactulose | Lactulose | 46 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Glipizide | Glipizide | 45 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 45 | 25 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Brilinta | Ticagrelor | 41 | suppressed |
| Nystatin | Nystatin | 41 | 18 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 40 | 39 |
| Azithromycin | Azithromycin | 39 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 16 |
| Anastrozole | Anastrozole | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Bumetanide | Bumetanide | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Constulose | Lactulose | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 21 |
| Ketoconazole | Ketoconazole | 31 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 19 |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Nyamyc | Nystatin | 30 | 18 |
| Renacidin | Citric Ac/Gluconolact/Mag Carb | 30 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 29 | suppressed |
| Timolol Maleate | Timolol Maleate | 29 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 28 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 27 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | 12 |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Pentoxifylline | Pentoxifylline | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | 13 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | 12 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | 16 |
| Clonidine | Clonidine | 21 | suppressed |
| Insulin Lispro | Insulin Lispro | 21 | suppressed |
| Lamotrigine Er | Lamotrigine | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Cyclosporine | Cyclosporine | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 20 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 19 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Klor-Con | Potassium Chloride | 16 | suppressed |
| Mesalamine Er | Mesalamine | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Enulose | Lactulose | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 11 |
| Lithium Carbonate | Lithium Carbonate | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Mesalamine Dr | Mesalamine | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Austedo Xr | Deutetrabenazine | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Budesonide Ec | Budesonide | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16.47 · 1 records | Novartis Pharmaceuticals Corporation | LEQVIO | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error